A polymorphism (Val66Met) in the gene encoding brain-derived neurotrophic factor (BDNF) has previously been associated with impaired hippocampal function and scores on the Logical Memory subtest of the Wechsler Memory Scale-Revised (WMS-R). Despite its widespread expression in the brain, there have been few studies examining the role of BDNF on cognitive domains, other than memory. We examined the association between BDNF Val66Met genotype and non-verbal reasoning, as measured by Raven's standard progressive matrices (Raven), in two cohorts of relatively healthy older people, one aged 79 (LBC1921) and the other aged 64 (ABC1936) years. LBC1921 and ABC1936 subjects had reasoning measured at age 11 years, using the Moray House Test (MHT), in the Scottish Mental Surveys of 1932 and 1947, respectively. BDNF genotype was significantly associated with later life Raven scores, controlling for sex, age 11 MHT score and cohort (P = 0.001). MHT, Verbal Fluency and Logical Memory scores were available, in later life, for LBC1921 only. BDNF genotype was significantly associated with age 79 MHT score, controlling for sex and age 11 MHT score (P = 0.016). In both significant associations, Met homozygotes scored significantly higher than heterozygotes and Val homozygotes. This study indicates that BDNF genotype contributes to age-related changes in reasoning skills, which are closely related to general intelligence.
Introduction
Age-related cognitive decline makes a substantial contribution to the reduction in quality of life experienced by older people. There are several factors believed to contribute to individual variation in the degree of cognitive change experienced with age. These include social, educational, medical and biological influences. 1 Genetic factors account for over half of the variance in adult cognitive ability and may still account for the majority of the variance in those over the age of 80 years. 2 We have previously shown that B50% of the variance in cognitive ability is stable between the ages of 11 and 79 years. 3 Therefore, cognitive ability in old age is probably influenced by some genetic variants that affect lifelong cognitive ability and some that are specific to old age ability.
This study forms part of a project investigating the genetic factors involved in individual differences in almost life-long cognitive change. The subjects were drawn from the Lothian Birth Cohort of 1921 (LBC1921), who are 550 surviving participants of the Scottish Mental Survey of 1932 (SMS1932) and the Aberdeen Birth Cohort of 1936 (ABC1936) who are 467 surviving participants of the Scottish Mental Survey of 1947 (SMS1947) [3] [4] [5] These are two unusual groups of people, in that there are mental ability scores for both of them at the age of 11 years, and then at 79 and 64, respectively, for SMS1932 and SMS1947. This makes them ideal for the study of cognitive ageing. We have already identified a number of genetic variants and interactions involving the genes APOE, NCSTN, KL, COMT, PRNP and DISC1 that influence either life-long cognitive ability and/or cognitive ageing in these cohorts [6] [7] [8] [9] [10] [11] [12] However, each of these polymorphisms accounts for less than 2.3% of the variance, and therefore there are likely to be many genetic factors involved in individual differences in cognitive ageing.
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors. It is widely expressed in the brain and is required for the survival, differentiation and maintenance of a variety of central nervous system neurons. 13 BDNF, and its receptor NTRK2 (also known as TRKB) are both highly expressed in the hippocampus 14 and have been implicated as important in hippocampal-dependent learning and memory, in non-human species (for a review, see Tyler et al. 15 ). BDNF is a critical factor for the formation of long-term potentiation (LTP) associated with memory. Indeed, knockout mouse experiments demonstrate that adult mice lacking BDNF exhibit hippocampal-dependent learning deficits. 16 Despite the widespread expression of BDNF in the brain, its potential role on other cognitive domains has received little attention.
There is also a growing body of indirect evidence linking BDNF with cognitive ageing. Oxidative stress, believed to be associated with cognitive ageing, 2 results in an increase in BDNF production, 17 implicating BDNF in antioxidant defence. Interestingly, in hippocampal pyramidal neurons and dentate granule cells in ageing monkeys, BDNF levels are reduced. 18 BDNF levels are increased in several regions of rodent brains in response to dietary restriction, a known contributor to reduction of oxidative stress and increased lifespan. 19 Together, these data suggest that BDNF genotype could influence individual variation in cognitive ageing.
A single putative common functional polymorphism, Val66Met (rs6265), has been identified within the coding region of BDNF. This polymorphism is within the pro-region of the protein and is therefore unlikely to affect the function of the mature protein. However, Mowla et al. 20 demonstrated that some pro-BDNF is released extracellularly and is biologically active. The Met allele has recently been implicated in abnormal hippocampal function in humans, during the N-back working memory task and a declarative memory task. 21, 22 Reduced intracellular trafficking of BDNF in neuronal cells 21, 23 and reduced hippocampal and frontal lobe grey matter volume and hippocampal formation volume have also been associated with the Met allele. 24, 25 Moreover, subjects homozygous for the Met allele produced lower scores than heterozygotes and Val homozygotes, on the Logical Memory subtest of the Wechsler Memory Scale-Revised (WMS-R). 21 However, on a second test of episodic memory, the California Verbal Learning Test (CVLT), no such association was detected. A second study, which combined the Met homozygote and heterozygote genotypes for analysis, concluded that the Met allele was associated with lower scores on the Logical Memory subtest of the WMS-R. 26 In a group of young healthy Chinese female subjects, Val homozygotes scored significantly higher than heterozygotes in the performance IQ subtest of the Wechsler Adult Intelligence Scale-Revised IQ test. 27 It is important to broaden the study of BDNF polymorphisms on cognitive phenotypes. During both young adulthood and in old age, the major cognitive domains all load on a general cognitive factor (g) that has a high heritability. 28, 29 Moreover, multivariate genetic analyses show that the majority of genes that affect individual differences in memory test scores also affect other areas of cognition. Owing to its widespread expression in the brain, BDNF is a good candidate for such a gene, that is, one whose influence on memory functions acts via its effect on general mental ability. BDNF levels are decreased in Alzheimer's disease (AD) [30] [31] [32] [33] and, interestingly, the Val not the Met allele has been associated with increased risk of AD. 34, 35 Other studies have failed to replicate such an association [36] [37] [38] [39] [40] and a recent study suggested that homozygosity for the Val allele is protective against AD in female subjects. 41 As AD is characterized by memory and other cognitive deficits, genes associated with the disease are also good candidates for association with non-pathological cognitive aging. 2 The genomic structure of BDNF has only recently been fully elucidated. 42 It consists of seven noncoding and one coding exons. Through the use of alternative promoters, translation start, splice and polyadenylation sites up to 40 different BDNF transcripts may be produced in a brain-region-specific pattern. Each transcript consists of a unique 5 0 and/or 3 0 untranslated region, but codes for a common mature protein. It has been reported that antidepressants differentially alter the expression of the BDNF isoforms in the adult rat brain, 43 and that the isoforms are differentially downregulated in AD 44 Although BDNF has been strongly implicated in both cognitive ability and age-related cognitive disease, there is little congruent data with regard to its role in human cognition.
We hypothesized that functional BDNF sequence variation is associated with individual variation in normal cognitive ageing. To test this hypothesis, we genotyped the common BDNF Val66Met polymorphism in two independent cohorts of relatively healthy subjects, for whom we have identical measures of both early and later life reasoning scores. At age 79 years, cognitive tests designed to assess verbal declarative memory and executive function enabled us to examine the effects of BDNF genotype on these specific domains. This was important, as not all cognitive domains are subject to the same degree of age-related decline. 2 In addition, we fully sequenced both the non-coding and coding exons in a subset of subjects to identify other potentially functional polymorphisms within BDNF.
Materials and methods

Subjects
We examined surviving participants from the Scottish Mental Surveys of 1932 and 1947 whose cognitive ability at age 11 years was known [3] [4] [5] Lothian birth cohort 1921 (LBC1921) Recruitment of LBC1921 was described previously. 3, 45 Mean age at re-test was 79.1 years (s.d. = 0.6 years), and all subjects were Caucasian and lived independently in the community. For this study, the following inclusion criteria were adopted for each subject: MHT score was available at age 11 years; Ravens Matrices score was available at age 79 years; there was no history of dementia; Mini-Mental State Examination (MMSE) score was 24 or greater and genotyping was successful for BDNF. This gave a total of 471 subjects (278 women, 193 men). A total of 460 subjects (274 women, 186 men) also had scores available for MHT, Verbal Fluency and Logical Memory at age 79 years.
Aberdeen birth cohort 1936 (ABC1936) ABC1936 was described previously. 46, 47 Mean age at re-test was 64.6 years (s.d. = 0.7 years), and all subjects were Caucasian and lived independently in the community. The following inclusion criteria were adopted for each subject: MHT score was available at age 11 years; Ravens Matrices score was available at age 64 years; MMSE score was 24 or greater and genotyping was successful for BDNF. This gave a total of 433 subjects (217 women, 216 men).
Cognitive testing
MMSE. MMSE
48 was used to screen both cohorts for dementia. The maximum score is 30. A score of less than 24 was used as an indicator of possible dementia.
MHT. All subjects took this general mental ability test at age 11 years, in the Scottish Mental Surveys of 1932 and 1947. LBC1921 re-took the test at about age 79 years. The test was previously described in detail. 3, 4, 49 It mainly assesses verbal reasoning skills, but also has some spatial, numerical and other items.
Raven's standard progressive matrices Non-verbal reasoning was examined in all subjects using Raven's Standard Progressive Matrices (Raven) . 50 This 60-item test was given with a time limit of 20 min. Each item of the test is a pattern with a missing piece. The subject has to induce the rules of the pattern and apply these rules to discover which of the answer options provides the correct completion of the pattern. Raven scores were available for all subjects (LBC1921 and ABC1936). The very-widely used and well-validated test of inductive reasoning is one of the group-based intelligence measures that is most closely related to general intelligence (g). 51 Verbal fluency LBC1921 subjects took the verbal fluency test, which is described as a test of prefrontal executive function. 52, 53 Subjects name as many words as possible in 1 min beginning with the letter C. The process is repeated for the letters F and L.
Logical Memory LBC1921 subjects took the Logical Memory test, which is a verbal declarative memory subtest from WMS-R. 54 A brief story with 25 memory elements is read to the subject who is asked to recall as many of the elements as possible (immediate recall). This is repeated for a second story. Later, after a fixed period, the subject is asked to recall the first and then the second stories (delayed recall). The total score (immediate þ delayed) was used. Principal components analysis of the two immediate and delayed recall scores showed a single component accounting for over 70% of the total variance.
The four mental ability tests described above have all been shown to be highly reliable, as demonstrated by repeat testing correlations within LBC1921: (v/v) DMSO, 1 Â PCR buffer and 2.5 mM MgCl 2 in a 25 ml total volume. An initial denaturation step of 6 min at 951C was followed by 35 cycles of PCR, consisting of 30 s at 941C, 30 s at 551C and 1 min at 721C, with a final 10 min extension at 721C. In total, 10 ml of each 403 bp PCR product was digested with 2 U NlaIII, in a 15 ml volume, for 2 h at 371C and the digested products were visualized on a 2% (w/v) agarose gel. Val homozygote samples produced a visible product of 245 bp. Met homozygote samples produced a visible product of 168 bp and heterozygotes produced two visible products of 245 and 168 bp.
Genotyping of Val66Met, in ABC1936, was carried out by the Welcome Trust Clinical Research Facility Genetics Core, Western General Hospital, Edinburgh (http://www.wtcrf.ed.ac.uk/genetics/index.htm) using TaqMan s technology (Applied Biosystems).
BDNF exon sequencing
Each of the eight BDNF exons, as defined in GenBank accession number AF411339, 42 were fully sequenced between 13 and 20 homozygote Val subjects and 18 and 20 homozygote Met subjects. Exons in which SNPs were identified, were fully sequenced in 20 Val/Val and 20 Met/Met subjects. Exons 1-7 were each amplified by a single PCR and exon 8 by three overlapping PCRs. Standard PCR conditions were as follows: 0.4 mM of each primer, 0.25 mM of each dNTP, 0.5 U AmpliTaq Gold, 10% (v/v) DMSO, 1 Â PCR buffer and 2.5 mM MgCl 2 in a 10 ml total volume. An initial denaturation step of 6 min at 951C was followed by 40 cycles of PCR, consisting of 30 s at 941C, 30 s at 551C and 1 min at 721C, with a final 10 min extension at 721C. Primer sequences and exceptions to standard PCR conditions are shown in Table 1 .
Sequencing reactions were performed, using both forward and reverse primers, by MRC technical services, MRC Human Genetics Unit, Edinburgh.
Statistical analysis
Raven scores were available for both LBC1921 and ABC1936, as were MHT scores from age 11 years. Therefore, data from the two cohorts were combined for statistical analysis. Cognitive ability scores for Verbal Fluency, Logical Memory and MHT in later life were also available for 460 LBC1921 subjects, and could be related to BDNF genotype in this cohort. The effect of BDNF genotype on cognitive outcome variables was analysed using general linear modelling. The between-subjects variables were: BDNF genotype (with three levels: Val/Val, Val/Met and Met/Met) and sex (two levels: male and female) and, where stated, cohort (two levels: LBC1921 and ABC1936). Where indicated, age 11 MHT score was included as a covariate. No sex by genotype, sex by cohort or genotype by cohort interactions were identified and therefore they were removed from all reported models. We report F and p values to indicate significance, and partial Z 2 values to indicate effect sizes.
Results
LBC1921 and ABC1936 Raven's Matrices analysis
The genotype frequencies of the 904 subjects (i.e. LBC1921 and ABC1936 combined) analysed in this study were as follows: Val/Val = 589; Val/Met = 280; Met/Met = 35. This did not differ significantly from Hardy-Weinberg equilibrium (w 2 = 0.06, NS). As larger samples sizes have greater power to detect associations, general linear modelling was performed using combined data from LBC1921 and ABC1936 to investigate the effect of BDNF genotype on Raven scores (non-verbal reasoning) in later life, on a relatively large sample size (n = 904). These models simultaneously allowed us to investigate the effect of Key: TD = touch down PCR, whereby an initial denaturation step of 5 min at 941C was followed by 20 cycles consisting of 45 s at 941C, 45 s at 651C (decreasing by 0.51C/cycle) and 1 min at 721C, followed by 20 cycles consisting of 45 s at 941C, 45 s at 551C and 1 min at 721C with a final 10 min extension at 721C. ageing on Raven scores as the two cohorts differed in age by 15 years.
Initially, a univariate analysis of variance was performed, with age 11 MHT score as the dependent variable. Sex, BDNF genotype and cohort were fixed effects. Neither BDNF genotype nor sex had a significant effect on age 11 MHT score (P > 0.10), indicating that MHT score in youth is not associated with BDNF genotype or sex in these two cohorts. Cohort was significantly associated with age 11 MHT score (F = 20.9, P < 0.001, Z 2 = 0.023), with LBC1921 having a higher mean childhood MHT score than ABC1936.
In the principal model, Raven score at the respective older ages was the dependent variable. Sex, BDNF genotype and cohort were fixed effects and the model was run with and without age 11 MHT score as a covariate. (Age 11 MHT score was included as a covariate to identify associations specifically with cognitive ageing.) A significant association between BDNF genotype and Raven score was detected (F = 6.4, P = 0.002, Z 2 = 0.014). This association remained significant and similar in effect size after adjusting for age 11 MHT score (F = 7.0, P = 0.001, Z 2 = 0.015). Figure 1 shows the Raven score raw data, and the estimated marginal means from the model including age 11 MHT scores as a covariate. Pairwise comparisons indicated that Met homozygotes scored significantly higher than heterozygotes and Val homozygotes (P = 0.001 and < 0.001 respectively). Age 11 MHT score contributed significantly to later life Raven score (F = 310.3, P < 0.001, Z 2 = 0.26), reflecting the fact that age 11 MHT score and later life Raven score are significantly correlated (r = 0.44, n = 904, P < 0.001). Cohort also had a significant independent effect on later life Raven scores, both before and after adjustment for age 11 MHT (F = 59.8, P < 0.001, Z 2 = 0.062; and F = 132.7, P < 0.001, Z 2 = 0.129, respectively). Individuals born in 1936 (aged 64 years) scored significantly higher than those born in 1921 (aged 79 years), a result which became larger in effect size after adjustment for the older sample's higher mean childhood MHT score. As reported previously, 3 sex also had a main effect on Raven score both before and after adjustment for age 11 MHT, with male subjects performing better than female subjects (P = 0.006 and < 0.001, respectively). BDNF genotype had a significant effect on MHT score at age 79 years both before and after controlling for age 11 MHT score (F = 6.1, P = 0.002, Z 2 = 0.026 and F = 4.2, P = 0.016, Z 2 = 0.018, respectively). Pairwise comparisons, after controlling for age 11 MHT score, showed that Met homozygotes scored significantly higher than both heterozygotes (P = 0.012) and Val homozygotes (P = 0.004) (Figure 2) . No association was identified between either Verbal Fluency or Logical Memory total scores and BDNF genotype in LBC1921 (P > 0.05). MHT score at age 11 years contributed to all cognitive outcomes at age 79 years (P < 0.001). Sex had a significant effect on age 79 MHT score, controlling for age 11 MHT score only, with male subjects scoring higher than female subjects (P = 0.003).
Previous studies identified an association between BDNF genotype and Logical Memory delayed score. 21, 26 Therefore, we analysed the immediate and delayed scores independently. No association was identified between BDNF genotype and either immediate or delayed scores, both before and after controlling for age 11 MHT score (P > 0.05).
The estimated marginal means (with 95% confidence intervals) for each of the outcome variables, adjusted for age 11 MHT score and sex and separated by BDNF Val66Met genotype, are shown in Table 2 . Table 2 also shows F, P and Z 2 values for the effects of BDNF genotype, age 11 MHT score and sex.
BDNF exon sequencing BDNF has the potential, by virtue of its multiple promoters, translation start, splice and polyadenylation sites, to tightly regulate its expression. As there is strong linkage disequlibrium across the BDNF gene, we speculated that the association of cognitive ageing with the Val66Met polymorphism might be because of linkage of this polymorphism with another polymorphism affecting regulation of gene expression. Therefore, we sequenced the seven non-coding exons and exon eight (coding exon) and flanking sequences in up to 20 LBC1921 Val and 20 LBC1921 Met homozygotes to identify variants that could potentially alter gene regulation. No polymorphisms were detected in or flanking exons one, two and four. No further polymorphisms were detected in the coding exon (exon eight). In total, four polymorphisms were detected; one in exon 3 (34260C > T), one in exon 5 (53620C > T (previously reported as 270C > T and 240C > T 55, 56 )), one in exon 6 (54418G > A) and one 5 0 of exon 7 (94594T > A (previously reported as À633T > A 57 )). In all cases, the Met homozygotes were homozygous for the common variant (Supplementary Table 1 ). Although the exon five SNP was previously associated with late-onset AD and epilepsy, none of the SNPs were predicted to alter splicing patterns or to create alternative translation or polyadenylation start sites.
Discussion
We have identified an association between the common BDNF Val66Met coding polymorphism and non-verbal reasoning, as tested by Raven's Standard Progressive Matrices, in two cohorts of older indivi- Table 2 The effects of BDNF genotype, age 11 MHT score and sex on cognitive ability scores at age 79 years (LBC1921) duals. This association was identified both before (P = 0.002) and after controlling for age 11 MHT score (P = 0.001), indicating that it is specifically with agerelated decline of non-verbal reasoning ability. Age 11 MHT score and age 79 Raven score are correlated (0.44) in these two cohorts. As we previously reported, age 11 MHT score was significantly higher in LBC1921 than ABC1936. This probably reflects the different social conditions in Lothian (principally, the City of Edinburgh) and Aberdeen and a greater migration of people with high age 11 MHT scores to Edinburgh, compared to Aberdeen, in the years between the initial testing at age 11 years and recruitment to our study. 9 It is also possible that the higher age 11 MHT score in LBC1921 is in part because of a survivor bias, as high psychometric intelligence has previously been associated with decreased mortality. 58 Homozygosity for the lesscommon Met allele was associated with better nonverbal reasoning ability in later life and BDNF genotype accounted for 1.5% of the variance in the Raven scores, after adjustment for sex, cohort and childhood ability differences. In all, 12.9% of the variance was accounted for by the cohort of the participants. ABC1936 who, at age 64, were 15 years younger than LBC1921 scored significantly better than LBC1921 (P < 0.001). No significant interaction between year of cohort and BDNF genotype was identified.
Using data from LBC1921, we were able to directly investigate the effect of BDNF genotype on age-related decline in verbal reasoning skills as we had access to MHT scores, for these individuals, at both ages 11 and 79 years. BDNF genotype was significantly associated with age 79 MHT scores both before and after controlling for age 11 MHT score. Homozygosity for the less-common Met allele was associated with better verbal reasoning at age 79 years and BDNF genotype accounted for 1.8% of the variance in the age 79 MHT scores, after adjustment for sex and childhood ability differences. No associations were identified between age 79 Logical Memory and Verbal Fluency scores and BDNF genotype, either before or after adjustment for childhood MHT scores, in LBC1921.
As far as we are aware, this study provides the first evidence that BDNF is associated with cognitive domains other than memory, and the first evidence that it is associated with age-related cognitive change in non-demented individuals. Reasoning ability, both verbal and non-verbal, is recognized as being central to human general psychometric intelligence, 51 and is particularly important with regard to cognitive ageing, because the ageing of specific cognitive domains occurs to a substantial extent via an effect of age on general intelligence. 59 Previous reports, using data from non-aged subjects, have suggested that the Met allele is associated with poorer performance in the delayed recall aspect of the Logical Memory subtest from WMS-R. 21, 26 We found no evidence for such an association in LBC1921. We also found no association between BDNF genotype and either immediate recall or total score. It has been suggested that the Met allele is associated with reduced hippocampal volume and impaired hippocampal function. However, owing to the low frequency of the Met allele, functional studies have combined Met/Met and Val/Met subjects or just compared Val/Met and Val/Val subjects 21, 22, [24] [25] [26] Further studies are required to determine the consequences of Met homozygosity on hippocampal (and other regions of the brain) function.
Interestingly, in some studies, the Val allele was previously associated with AD, a disorder affecting both memory and reasoning abilities. 34, 35 It is possible that early in life the Val allele is associated with better cognitive ability, specifically verbal declarative memory. We were unable to test this hypothesis directly as we do not have scores for Logical Memory in youth, although it is supported by previous studies. 21, 26 However, as individuals age, possession of the Val allele becomes detrimental causing greater cognitive decline, particularly of reasoning abilities, which in some individuals may lead to AD. Alternatively, the Met allele, although associated with poorer performance in tests of verbal declarative memory early in life, as suggested by previous studies, may be protective against cognitive decline, particularly of reasoning abilities and AD. It should also be noted that association studies, particularly those carried out on relatively small subject numbers, are prone to Type 1 error and therefore further replication of all these studies is required before we have a more definitive answer to the question of whether or not BDNF genotype is associated with cognitive ability/decline. It is also important that a variety of cognitive domains be tested.
We found no evidence for functional polymorphisms, linked to Val66Met, that are stronger candidates for association with cognitive ability. The BDNF noncoding 53620C > T SNP was identified in LBC1921. This was previously associated with AD, 55, 60 with the T allele conferring increased risk of AD. In LBC1921, of the 20 Val66 and 20 Met66 homozygotes sequenced, only two 53620C > T carriers were identified; both were Val homozygotes. No 53620T homozygotes were detected. It is possible that a functional polymorphism in one of the promoters or introns of BDNF may be the true SNP associated with cognitive ability, cognitive decline and/or AD. However, this study supports the hypothesis that BDNF Val66Met is a functional polymorphism that contributes to variance in age-related reasoning abilities.
